Biofrontera Inc. Annual Report - How They Did This Year

Hey there! Think of this as our chat about Biofrontera Inc.'s latest annual report. This report covers the fiscal year ended December 31, 2025. I'll break down what they've been up to. We'll also see how their business is doing. This might help you as an investor. You won't have to wade through all the dense financial talk.

Here's what we'll cover:

1. What does this company do and how did they perform this year?

   • Biofrontera Inc. is a Woburn, Massachusetts company. Its stock trades on Nasdaq as BFRI (and BFRIW for its warrants). This report covers their performance for the year ending December 31, 2025.
   • Biofrontera Inc. is a biopharmaceutical company. They sell skin-related medical products in the U.S. Their main product is Ameluz® gel. The FDA approved it with their BF-RhodoLED® lamp. Doctors use it to treat mild-to-moderate actinic keratosis (AK) on the face and scalp. AK is a common pre-cancerous skin lesion from sun exposure.
   • It's a relatively small company. As of June 30, 2025, its publicly traded stock was worth about $6.9 million. They had about 11.6 million shares of stock available as of March 16, 2026. For 2025, Biofrontera Inc. brought in $28.5 million in total sales. This was a 12% increase from $25.4 million last year. Despite this sales growth, the company lost $12.3 million for the year.
   • The company is a "Non-accelerated filer," a "Smaller reporting company," and an "Emerging growth company." This means it's a smaller public company. It has fewer reporting rules than larger corporations. This can offer flexibility. It also suggests an earlier growth stage or smaller market presence. For investors, this often means higher risk. Controls might be less robust, resources limited, and products less diverse. However, it also offers higher growth potential if their main products succeed.

2. Financial performance - sales, profit, growth metrics

   • For 2025, Biofrontera Inc. reported $28.5 million in total sales. This was up 12% from $25.4 million in 2024. More doctors adopted Ameluz® in the U.S. market. Patients also demanded it more. This drove the sales growth.
   • The company reported $21.3 million in gross profit, meaning a gross margin of about 74.7% for 2025. This was consistent with last year. Operating costs totaled $33.6 million, including research and development (R&D) and sales, general, and administrative (SG&A) expenses. R&D costs were $5.8 million, mainly funding ongoing clinical trials for new Ameluz® uses. SG&A costs were $27.8 million, driven by sales force expansion and marketing initiatives.
   • As a result, Biofrontera Inc. lost $12.3 million in 2025, compared to a $10.5 million loss in 2024. This means a loss of $1.06 per share, based on 11.6 million average shares. Last year, the loss was $0.91 per share. The company invested more in sales and product development, which increased the loss, outweighing sales growth.

3. Major wins and challenges this year

   • Major Wins:
     • Sales Growth: Sales grew 12% to $28.5 million in 2025, showing Ameluz® is gaining market share.
     • Clinical Progress: They finished enrolling patients for a Phase 3 trial testing Ameluz® for basal cell carcinoma (BCC). This is a big step to expand the product's uses and market, with top results expected in late 2026.
     • Market Expansion: More dermatologists prescribed Ameluz® in 2025, up 15%, indicating doctors trust and use their light-based therapy more.
   • Challenges:
     • Continued Losses: Sales grew, but the company's loss increased to $12.3 million, mainly due to big investments in sales, marketing, and R&D. This raises concerns about when they will make a profit.
     • Cash Burn: The company used about $10.5 million in cash from operations in 2025. This high cash burn rate means they must manage their cash carefully.
     • Intense Competition: They faced tough competition for actinic keratosis treatments, with other creams and cryotherapy (freezing) potentially affecting their prices and market share.

4. Financial health - cash, debt, liquidity

   • As of December 31, 2025, Biofrontera Inc. had $7.2 million in cash, down from $17.7 million at the end of 2024. The company's loss and $10.5 million used in operations caused this drop.
   • The company's working capital was $10.1 million as of December 31, 2025 (current assets minus current liabilities), down from $19.5 million last year. This shows less short-term financial flexibility.
   • Biofrontera Inc. had little long-term debt, with total long-term obligations of $1.8 million, mainly lease payments. They have no major bank loans or credit lines.
   • With current cash and ongoing losses, the company stated a concern that they might not operate for another year without more funding. This 'going concern' warning means investors should know they might need to raise more money, potentially through issuing more shares or taking on debt, which could reduce existing ownership percentages.

5. Key risks that could hurt the stock price

   • Regulatory Approval Risk: The company's future growth depends heavily on FDA approval for new Ameluz® uses, like basal cell carcinoma. Trial failures or delays could hurt future sales and investor trust.
   • Commercialization and Market Acceptance Risk: Ameluz®'s success depends on doctors using it, good insurance coverage, and patient acceptance. Strong competition for actinic keratosis treatments could limit their market share.
   • Funding and Liquidity Risk: Biofrontera Inc. has ongoing losses and uses cash quickly. They will need more money to fund operations, clinical development, and sales growth. If they can't raise enough money easily, product development could slow, sales activities might shrink, or the company might even stop operating.
   • Intellectual Property Risk: The company's success relies on protecting its intellectual property, including patents for Ameluz® and BF-RhodoLED®. If these patents are challenged or expire, generic competitors could emerge, greatly reducing their profit.
   • Product Liability Risk: As a drug company, Biofrontera Inc. faces product liability risks if Ameluz® or BF-RhodoLED® cause bad side effects or are found ineffective. Such claims could mean big legal costs, damages, and harm to their reputation.

6. Competitive positioning

   • Biofrontera Inc. operates in the very competitive skin care market, specifically targeting actinic keratosis (AK). Their main product, Ameluz® with BF-RhodoLED®, competes with several existing treatments. Key competitors include other light-based therapies like Levulan® Kerastick®, prescription creams like Picato®, Efudex®, and Aldara®, and non-drug treatments like cryotherapy (freezing) and surgery.
   • Biofrontera highlights Ameluz®'s proven effectiveness and safety, and its convenience for treating larger areas of sun-damaged skin. They have a small share of the AK market, but focus on standing out using clinical data, doctor education, and a dedicated sales team. Their strategy highlights Ameluz®'s better cosmetic results and high clearance rates compared to some other treatments.

7. Leadership or strategy changes

   • No major changes happened in the leadership team during 2025. The company kept its main strategy, focusing on growing Ameluz® sales in the U.S. through better sales teams and targeted marketing. They also plan to develop Ameluz® for new uses, like basal cell carcinoma, to expand their market and diversify sales long-term.

8. Future outlook

   • Biofrontera Inc. has an optimistic but careful outlook for 2026. The company expects Ameluz® sales to keep growing, projecting sales between $32 million and $35 million. More market reach and doctor adoption will drive this, and they plan to keep investing in sales and marketing to support this growth.
   • A key focus for 2026 is advancing their clinical pipeline, including expected top results from the Ameluz® Phase 3 trial for basal cell carcinoma. Good results could greatly reduce risk for product expansion and would be a major boost for the stock.
   • Financially, the company wants to manage costs better to reduce their loss, but they don't expect profit in 2026. They know they need more funding for operations and development, which is crucial for their long-term survival.

9. Market trends or regulatory changes affecting them

   • Aging Population and Skin Cancer Incidence: An aging global population helps Biofrontera Inc., as more older people mean more actinic keratosis and other skin cancers, creating more patients for their products.
   • Demand for Non-Invasive Treatments: Patients increasingly prefer less invasive and better-looking treatments for skin conditions. Ameluz® light therapy fits this trend, offering an effective, non-surgical solution for AK.
   • Healthcare Reimbursement Policies: Changes in healthcare payment policies could affect Ameluz®, especially for Medicare and private insurers, impacting its availability and affordability. Good coverage decisions can boost sales, while strict policies could slow market growth.
   • FDA Regulatory Environment: The FDA's changing drug approval rules affect new products, influencing the time and cost to bring new uses to market. Stricter rules could challenge Biofrontera's product development.
   • Generic Competition: Generic versions of competing AK treatments are a risk. Future generic Ameluz® after patent expiry is also a threat, which could hurt market share and pricing power long-term.

So, there you have it – a look at Biofrontera Inc.'s year. Weighing the sales growth and clinical progress against the ongoing losses and funding needs is key for any investment decision.